Sarepta Therapeutics ( NASDAQ: SRPT) faces an “arduous and treacherous path” to bring its gene therapy Elevidys back to market, according to a STAT report citing a senior FDA official, suggesting the ...

We recently published 10 Big Names Get Slammed. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is one of the biggest losers on ...

What Happened? Shares of life sciences company Azenta (NASDAQ:AZTA) jumped 5.7% in the afternoon session after the investment firm Stephens initiated coverage on the life sciences company. The firm ...

What Happened? Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE) jumped 24.1% in the afternoon session after ...

Sarepta Therapeutics' recent setbacks and restructuring have pressured Arrowhead's share price. Read why I am reiterating my bullish rating on ARWR stock.

The FDA had made the request Friday, which Sarepta initially rebuffed, following the death of a third patient treated with one of the firm's gene therapies.

Asian markets are mixed after U.S. stock indexes hit new records on Monday. Oil prices fell and U.S. futures were little ...

U.S. stock indexes inched their way to more records on Monday to kick off a week full of profit updates from big U.S.

Sarepta Therapeutics (SRPT) said late Monday it will pause all shipments of its Duchenne muscular dystrophy gene therapy, ...

H.C. Wainwright sets a rare $0 target for Sarepta Therapeutics amid FDA scrutiny over its Duchenne muscular dystrophy gene therapy Elevidys. Read more here.

Shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) plunged 10% after the company disclosed that the U.S. Food and Drug ...